Evidence map›Paper›PMID 3782631›Full record

Trial reportJournal of the American College of Cardiology1986

Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin.

P L Canner, K G Berge, N K Wenger, J Stamler, L Friedman, R J Prineas, W Friedewald

2 registry-linked trialsAbstract readClinical TrialControlled Clinical Trial
PubMed Publisher
In one paragraph

Trial report in Journal of the American College of Cardiology, 1986. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT00000483. Cited by 359 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
359citing papers in PubMed, 8 pooled it
66.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00000483 nacompleted

Coronary Drug Project Mortality Surveillance

Ran1981Registered outcomes0Posted comparisons0ConditionsCardiovascular Diseases, Coronary Disease, Heart Diseases, Myocardial InfarctionArmsclofibrate, dextrothyroxine sodium, Estrogen, niacin
PMID 2044644PMID 6675887PMID 6675888other papers from this trial
Open the trial in the graph
NCT06966583 phase1not yet recruitingnot on this mapstarted 2025, after this paper: background citation

Safety and Preliminary Efficacy Study of NAD+Supplements (NMN) Combined With Radioimmunotherapy in Advanced Non Small Cell Lung Cancer Patients

TypeinterventionalSponsorSichuan UniversityRan2025 to 2027Enrolled20ConditionsSolid Tumor, Non Small Cell Lung CancerArmsNAD supplement, Radiotherapy, Immunotherapy
3 · Its place in the literature

Who cites it

359 citing papers in PubMed, 8 syntheses or guidelines pooled it, 1,838 citations in OpenAlex.

  1. Pooled it
  2. Niacin for primary and secondary prevention of cardiovascular events.The Cochrane database of systematic reviews · 2017 · on this map
    Pooled it
  3. Pooled it
  4. Guideline
  5. Guideline
  6. Guideline
  7. Guideline
  8. Guideline
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

299 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

P L Canner
K G Berge
N K Wenger
J Stamler
L Friedman
R J Prineas
W Friedewald
Maryland Medical Research Institute · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Coronary Drug Project was conducted between 1966 and 1975 to assess the long-term efficacy and safety of five lipid-influencing drugs in 8,341 men aged 30 to 64 years with electrocardiogram-documented previous myocardial infarction. The two estrogen regimens and dextrothyroxine were discontinued early because of adverse effects. No evidence of efficacy was found for the clofibrate treatment. Niacin treatment showed modest benefit in decreasing definite nonfatal recurrent myocardial infarction but did not decrease total mortality. With a mean follow-up of 15 years, nearly 9 years after termination of the trial, mortality from all causes in each of the drug groups, except for niacin, was similar to that in the placebo group. Mortality in the niacin group was 11% lower than in the placebo group (52.0 versus 58.2%; p = 0.0004). This late benefit of niacin, occurring after discontinuation of the drug, may be a result of a translation into a mortality benefit over subsequent years of the early favorable effect of niacin in decreasing nonfatal reinfarction or a result of the cholesterol-lowering effect of niacin, or both.

Indexed as

AdultAspirinClofibrateDextrothyroxineEstrogensFollow-Up StudiesHumansMaleMiddle AgedMyocardial InfarctionNiacinTime FactorsAspirinClofibrateDextrothyroxineEstrogensNiacin

Identifiers

PMID3782631
OpenAlexW2115572248

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.